Business Wire

Ant Group Recognized as Top 100 Global Innovator 2023

16.2.2023 14:09:00 EET | Business Wire | Press release

Share

Ant Group, a global digital technology provider, has been recognized as a Top 100 Global Innovator™ 2023 by Clarivate™, a global leader in connecting people and organizations to intelligence they can trust to transform their world. This marks the second year in a row that Ant Group has received this prestigious recognition. Clarivate’s annual list identifies organizations at the pinnacle of the global innovation landscape by measuring excellence in innovativeness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005447/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ant Group Recognized as Top 100 Global Innovator 2023 (Graphic: Business Wire)

Gordon Samson, Chief Product Officer, Clarivate, said, “Ant Group’s incorporation in the Top 100 Global Innovators 2023 is due to its consistent above-the-bar innovation performance, especially its exceptional influence on the research ideas of other innovators. Together with all Top 100 Global Innovators, Ant Group fully appreciates that innovative ideas and solutions to current challenges not only bring rewards to its business but foster genuine improvements in society.”

In 2022, Ant Group obtained over 4,000 new patents globally. Since 2016, the number of patents held by Ant Group has increased more than 40 times to over 17,000. As a result of this consistent performance, Ant Group has been named one of the top innovators, along with companies such as Alphabet, Qualcomm, and GE.

“We are delighted to have our innovation capabilities recognized by Clarivate as one of the Top 100 Global Innovators 2023,” said Shen PAN, Director of Patents at Ant Group. “We are committed to supporting consumers and businesses in building trust and enabling the digital transformation of industries through our innovations in key technologies such as blockchain, privacy computing, security technology, and databases.”

Ant Group's consistency and strength in innovation is also reflected in various industry reports. In January 2023, LexisNexis Legal & Professional, a provider of science-backed patent analytics technology, named Ant Group as one of the companies shaping the future of science and technology in its “Innovation Momentum 2023: The Global Top 100” report. The report is based on an analysis of shifts in patent portfolio strength over the previous two years. In March 2022, Ant Group also topped the “2022 Global Privacy Computing Patents List” compiled by IPRdaily and IncoPat, ranking first for the second year in a row with 1,152 patents.

Learn more about Top 100 Global Innovators 2023 and who features on this year’s list here.

Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.

For full information on the methodology used to identify the 2023 list, see here.

About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms.

Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Clarivate
Jack Wan, External Communications Director
newsroom@clarivate.com

Ant Group
Le SHEN, International Communications
globalcomms@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye